|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT00723801 |
|
Date of registration:
|
25/07/2008 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
|
|
Scientific title:
|
Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome |
|
Date of first enrolment:
|
October 2007 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00723801 |
|
Study type:
|
Interventional |
|
Study design:
|
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Mark A Creager, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Brigham and Women;s Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age greater than 25 years
- Clinical Marfan Syndrome
Exclusion Criteria:
- Previous aortic or cardiac surgery
- Pregnancy
- Renal Insufficiency
- Medication intolerance
Age minimum:
25 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Marfan Syndrome
|
|
Intervention(s)
|
|
Drug: Losartan
|
|
Drug: Atenolol
|
|
Primary Outcome(s)
|
|
Aortic Biophysical Properties - Pulse Wave Velocity
[Time Frame: Baseline and 6 months]
|
|
Secondary Outcome(s)
|
|
Diastolic Function - Ejection Fraction
[Time Frame: Baseline and 6 months]
|
|
Secondary ID(s)
|
|
2007p-001762
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|